Back to Insider Trading View Full Company Profile

ALLO

UNKNOWN

Allogene Therapeutics, Inc.

CIK: 0001737287

Strong Sell (90% confidence)

Last activity: 2 weeks ago

Financial Metrics

As of Dec 31, 2025 (10-K)

Total Cash $258.30M

Insider Roster (6 total, 6 active)

Insider Buys Sells Net Value Holdings
Chang David D
President and CEO
0 2 -$289K
5,150,599 shares
$12.72M
Roberts Zachary
EVP of R&D
0 2 -$104K
581,166 shares
$1.03M
Beneski Benjamin Machinas
SVP, Chief Technical Officer
0 3 -$44K
198,205 shares
$490K
Parker Geoffrey M.
CHIEF FINANCIAL OFFICER
0 1 -$42K
1,252,795 shares
$2.20M
Douglas Earl Martin
SVP, General Counsel
0 1 -$40K
564,948 shares
$994K
Yoshiyama Annie
SVP, Finance
0 1 -$7K
130,322 shares
$224K

Recent Transactions

SELL Chang David D (President and CEO)

47,763 shares @ $2.47

$118K

Mar 16, 2026

Conviction: | View SEC Filing →
SELL Beneski Benjamin Machinas (SVP, Chief Technical Officer)

4,835 shares @ $2.47

$12K

Mar 16, 2026

Conviction: | View SEC Filing →
SELL Beneski Benjamin Machinas (SVP, Chief Technical Officer)

7,132 shares @ $2.60

$19K

Mar 2, 2026

Conviction: | View SEC Filing →
SELL Chang David D (President and CEO)

95,269 shares @ $1.80

$171K

Feb 2, 2026

Conviction: | View SEC Filing →
SELL Roberts Zachary (EVP of R&D)

35,700 shares @ $1.77

$63K

Feb 2, 2026

Conviction: | View SEC Filing →
SELL Parker Geoffrey M. (CHIEF FINANCIAL OFFICER)

24,001 shares @ $1.76

$42K

Feb 2, 2026

Conviction: | View SEC Filing →
SELL Douglas Earl Martin (SVP, General Counsel)

22,900 shares @ $1.76

$40K

Feb 2, 2026

Conviction: | View SEC Filing →
SELL Beneski Benjamin Machinas (SVP, Chief Technical Officer)

7,549 shares @ $1.73

$13K

Feb 2, 2026

Conviction: | View SEC Filing →
SELL Yoshiyama Annie (SVP, Finance)

4,167 shares @ $1.72

$7K

Feb 2, 2026

Conviction: | View SEC Filing →
SELL Roberts Zachary (EVP of R&D)

26,269 shares @ $1.56

$41K

Jan 21, 2026

Conviction: | View SEC Filing →

⚠️ Important Disclaimer

• This is AI-generated analysis for educational purposes only, not financial advice.

• Insider trading data is derived from SEC Form 4 filings and may contain errors.

• Always conduct your own research and consult qualified financial advisors before making investment decisions.